Finished Formulation

Finished Formulation

Finished formulation manufacturing is the stage of pharmaceutical production in which an active pharmaceutical ingredient (API) and suitable excipients are converted into a complete, patient-ready dosage form such as a tablet, capsule, injection, syrup, suspension, ointment, cream, dry syrup, powder, or other finished pharmaceutical product.

Taj Pharma has developed manufacturing capabilities covering multiple finished dosage forms and provides formulation manufacturing for both domestic and export markets. Its official manufacturing information describes dedicated modules for oral solid dosages, small-volume parenterals, injections, dry injections, syrups and suspensions, ointments, and dry syrups.

What Is Finished Formulation Manufacturing?

Finished formulation manufacturing transforms pharmaceutical ingredients into a finished medicine that can be packaged, released, distributed, and supplied to the intended market.

The process extends beyond simply mixing an API with excipients. It involves a controlled sequence of activities that can include:

Raw-material qualification → dispensing → formulation → processing → in-process controls → finished-product testing → packaging → quality release → distribution

Depending on the dosage form, the manufacturing process can involve granulation, blending, compression, encapsulation, coating, filling, homogenization, sterilization or aseptic processing, drying, filling, sealing, and packaging.

At Taj Pharma, the manufacturing infrastructure is organized around dedicated dosage-form capabilities, allowing different pharmaceutical products to be manufactured using equipment and production areas appropriate to their formulation requirements.

Taj Pharma Finished Formulation Manufacturing Capabilities

Taj Pharma’s published manufacturing information identifies a broad finished-formulation portfolio.

Oral Solid Dosage Manufacturing

The manufacturing network includes:

• Tablets
• Capsules
• Effervescent tablets
• Dry blended powders
• Granules
• Oral sachets
• Oral jelly

The official Taj Pharma India manufacturing information states a capacity of 120 million tablets and 40 million capsules per month at its Sarigam facility, alongside additional capacities for dry blended powders/granules, effervescent tablets, oral jelly, creams/ointments, and oral sachets.

Liquid and Semi-Solid Formulations

Finished formulation capabilities also include:

• Syrups
• Suspensions
• Dry syrups
• Creams
• Ointments
• Oral liquids

Taj Pharma’s published product and manufacturing information also identifies creams, ointments, gels, oral liquids, and other dosage forms within its broader formulation manufacturing portfolio.

Injectable Formulations

The manufacturing setup includes specialized injectable capabilities, including:

• Liquid injections
• Ampoule injections
• Vial injections
• Dry powder injections
• Lyophilized injections
• Small-volume parenterals
• Prefilled syringes
• Large-volume parenterals

The Taj Pharma manufacturing page specifically identifies dedicated modules for Small Volume Parenterals, Injection, and Dry Injection.

Finished Tablet Manufacturing

Tablets are among the most widely used pharmaceutical dosage forms and require controlled processing from raw-material dispensing through compression and packaging.

A typical tablet manufacturing workflow can include:

1. Raw-material dispensing
2. Sifting
3. Granulation where applicable
4. Drying
5. Milling
6. Blending
7. Lubrication
8. Compression
9. Coating where applicable
10. Inspection
11. Packaging
12. Finished-product testing
13. Quality release

The exact manufacturing process depends on the formulation and may use processes such as direct compression, wet granulation, dry granulation, or other validated manufacturing approaches.

Taj Pharma’s published manufacturing information states a 120 million tablets per month production capacity at its Sarigam facility.

For customers requiring large-volume pharmaceutical production, this scale can support commercial manufacturing programs subject to product suitability, manufacturing scheduling, regulatory requirements, and available capacity.

Finished Capsule Manufacturing

Capsules provide another major oral solid dosage platform.

Capsule manufacturing generally involves preparation of the formulation blend followed by controlled capsule filling and subsequent inspection and packaging.

Key activities can include:

• API and excipient dispensing
• Sifting
• Blending
• Granulation where required
• Lubrication
• Capsule filling
• Weight control
• Inspection
• Packaging
• Finished-product testing

Taj Pharma’s published capacity information identifies 40 million capsules per month at its Sarigam manufacturing facility.

Effervescent Tablet Manufacturing

Effervescent tablets represent a specialized oral dosage form designed to dissolve or disperse in water before administration.

Manufacturing requires careful control of formulation components, moisture exposure, blending, compression, packaging, and storage.

Taj Pharma’s published Sarigam facility information identifies a stated capacity of 20 million effervescent tablets per month.

Because moisture management can be important for effervescent products, appropriate packaging and environmental controls form an important part of the finished-product manufacturing strategy.

Dry Powder and Granule Manufacturing

Taj Pharma’s finished formulation manufacturing capabilities also include dry blended powders and granules.

These products can require controlled:

• Material dispensing
• Particle-size management
• Sifting
• Blending
• Granulation
• Drying where applicable
• Milling
• Packaging

The published Sarigam facility information gives a stated capacity of 36,000 kg per month for dry blended powders/granules.

Oral Jelly Manufacturing

Oral jelly provides an alternative pharmaceutical dosage format and is included among Taj Pharma’s finished formulation capabilities.

The Sarigam facility has a published stated capacity of 60 million oral jelly units per month.

Manufacturing may involve controlled preparation of the formulation base, incorporation of active ingredients, homogenization, filling, setting or cooling where applicable, inspection, and packaging.

Cream and Ointment Manufacturing

Taj Pharma also manufactures topical formulations, including creams and ointments.

The manufacturing process for topical products can involve:

• Raw-material dispensing
• Phase preparation
• Heating where required
• Mixing
• Homogenization
• API incorporation
• Cooling
• Bulk holding
• Filling
• Tube or container sealing
• Packaging

The published Sarigam capacity for creams and ointments is 40 million units per month.

Topical manufacturing requires appropriate controls over formulation uniformity, physical characteristics, microbial quality where applicable, packaging integrity, and finished-product specifications.

Oral Sachet Manufacturing

Oral sachets provide a convenient single-dose packaging format for suitable powders, granules, and other oral formulations.

Taj Pharma’s published manufacturing information identifies a stated capacity of 3 million oral sachets per month at its Sarigam facility.

Sachet manufacturing combines formulation control with accurate filling, sealing, packaging, and product protection.

Syrup, Suspension and Dry Syrup Manufacturing

Liquid and reconstitutable formulations require specialized processing controls.

Taj Pharma’s manufacturing information identifies dedicated manufacturing modules for syrups and suspensions and dry syrups.

Depending on the formulation, production may include:

• Water preparation
• Excipient dissolution
• API dispersion or dissolution
• Mixing
• Homogenization
• pH adjustment
• Volume adjustment
• Filtration where applicable
• Bulk testing
• Filling
• Sealing
• Labeling
• Packaging

Suspensions require particular attention to particle dispersion and physical stability, while dry syrups require controlled powder blending and packaging appropriate to the product.

Injectable Finished Formulation Manufacturing

Injectable products represent a technically specialized segment of finished formulation manufacturing.

Taj Pharma’s published manufacturing information identifies capabilities covering small-volume parenterals, injections, dry injections, liquid injections, and other injectable formats.

The manufacturing process depends on the specific product and may involve:

Raw-material preparation → solution or suspension preparation → filtration where applicable → filling → sealing → inspection → sterilization or aseptic processing as applicable → labeling → packaging → quality release

Sterile products require particularly stringent control of manufacturing environments, equipment, personnel practices, microbiological quality, container closure, and process controls.

Lyophilized and Dry Injection Manufacturing

Lyophilized formulations use freeze-drying technology to convert an appropriate liquid formulation into a dry product.

A typical lyophilization process involves stages such as:

1. Formulation preparation
2. Filling into suitable containers
3. Loading into the lyophilizer
4. Freezing
5. Primary drying
6. Secondary drying
7. Stoppering
8. Inspection
9. Packaging

Taj Pharma’s published manufacturing information identifies dry injections and lyophilized injections within its broader injectable manufacturing capabilities.

Pharmaceutical Manufacturing Quality System

Finished formulation manufacturing depends on an integrated quality system rather than final-product testing alone.

Taj Pharma’s published information describes quality-focused infrastructure including analytical laboratories, microbiology laboratories, clean-room environments, production systems, packaging systems, and quality-control activities.

Quality activities can extend across the complete manufacturing chain:

Approved raw materials

↓

Controlled manufacturing process

↓

In-process testing

↓

Finished-product testing

↓

Packaging verification

↓

Quality review

↓

Batch release

The precise controls and acceptance criteria depend on the product, dosage form, regulatory market, and approved specifications.

Finished Formulation Manufacturing for Domestic and Export Markets

Taj Pharma’s official manufacturing information states that its finished dosage facility caters to export and domestic markets.

For export manufacturing, requirements can vary substantially between countries. Finished formulation manufacturing may therefore need to consider:

• Target-market registration
• Approved formulation
• Product specifications
• Packaging requirements
• Labeling requirements
• Stability requirements
• Manufacturing-site requirements
• Regulatory documentation
• Batch documentation
• Certificates of Analysis
• Market-specific release requirements

A product manufactured for one market may require different packaging, labeling, specifications, or documentation for another market.

Finished Formulation Manufacturing for Contract Manufacturing

Finished formulations are also an important component of third-party and contract pharmaceutical manufacturing.

Taj Pharma describes itself as a third-party pharmaceutical manufacturer and provides a broad range of dosage-form manufacturing capabilities.

A contract manufacturing project can involve:

Product Evaluation

The formulation, strength, dosage form, target quantity, packaging, and target market are evaluated.

Technical Assessment

The formulation is assessed against available equipment, manufacturing technology, capacity, and applicable quality requirements.

Documentation

Relevant technical, quality, regulatory, and commercial documentation is coordinated.

Manufacturing

Commercial production is scheduled according to the agreed manufacturing plan.

Quality Control

Applicable raw materials, in-process materials, and finished products undergo required testing.

Packaging

The finished product is packed according to approved specifications.

Release and Supply

Following applicable quality review and release procedures, the finished product can proceed to supply according to the agreed market and commercial requirements.

Finished Formulation Manufacturing Capacity

The published Sarigam manufacturing figures provide an indication of the scale of the formulation operation:

• Tablets: 120 million units/month
• Capsules: 40 million units/month
• Dry blended powders/granules: 36,000 kg/month
• Effervescent tablets: 20 million units/month
• Oral jelly: 60 million units/month
• Creams/ointments: 40 million units/month
• Oral sachets: 3 million units/month

These figures are stated facility capacities rather than a guarantee of available production capacity for every product or month. Actual manufacturing availability depends on product requirements, production schedules, regulatory status, equipment allocation, batch sizes, and commercial agreements.

Why Finished Formulation Manufacturing Matters

Finished formulation manufacturing connects pharmaceutical development with the actual supply of patient-ready medicines.

A strong formulation manufacturing platform needs to integrate:

• Formulation technology
• Manufacturing equipment
• Quality assurance
• Quality control
• Regulatory compliance
• Process controls
• Packaging
• Stability
• Documentation
• Production planning
• Supply-chain coordination

Taj Pharma’s published capabilities combine multiple dosage forms with dedicated manufacturing infrastructure, R&D and pilot capabilities, analytical and microbiological support, and commercial manufacturing operations.

Frequently Asked Questions

What is finished formulation manufacturing?

Finished formulation manufacturing is the conversion of APIs and excipients into a complete pharmaceutical dosage form that can undergo quality release, packaging, distribution, and market supply.

What finished formulations does Taj Pharma manufacture?

Published Taj Pharma information covers tablets, capsules, syrups, dry syrups, injectables, dry injections, small-volume parenterals, creams, ointments, gels, oral liquids, powders, effervescent tablets, oral jelly, oral sachets, and other formulation categories.

Does Taj Pharma manufacture tablets and capsules?

Yes. Taj Pharma’s published Sarigam facility information states capacities of 120 million tablets and 40 million capsules per month.

Does Taj Pharma offer third-party manufacturing?

Taj Pharma’s published information describes its activities in third-party pharmaceutical manufacturing and contract manufacturing.

Does Taj Pharma manufacture injectable formulations?

Yes. Published manufacturing information identifies capabilities for injections, dry injections, and small-volume parenterals, alongside other injectable formats.

Does Taj Pharma manufacture creams and ointments?

Yes. The Sarigam facility’s published information includes cream and ointment manufacturing, with a stated capacity of 40 million units per month.

Does Taj Pharma manufacture products for export markets?

Yes. Taj Pharma’s manufacturing information states that its finished dosage facility caters to export and domestic markets.

Taj Pharma’s finished formulation manufacturing platform encompasses a broad range of pharmaceutical dosage forms, from high-volume tablets and capsules to injectable products, syrups, suspensions, dry syrups, creams, ointments, powders, granules, effervescent tablets, oral jelly, and sachets.

Its published manufacturing infrastructure includes dedicated production modules, R&D and pilot capabilities, commercial manufacturing operations, analytical and microbiological support, and substantial stated production capacities.

With a manufacturing model serving domestic and export markets, Taj Pharma can support finished formulation requirements ranging from conventional oral solid dosage products to specialized pharmaceutical formats. The combination of dosage-form diversity, manufacturing infrastructure, quality systems, and contract-manufacturing capabilities makes finished formulation manufacturing a significant component of Taj Pharma’s pharmaceutical services.

For commercial enquiries, the appropriate manufacturing pathway should be evaluated against the product composition, dosage form, strength, target market, regulatory status, required quantity, packaging, and technical requirements before production commitments are made.